Cellectis Files IND For Talen-Edited 'Off-The-Shelf' CAR-T Candidate
Cellectis has filed an IND for US testing of its TALEN-edited CAR-T immune-oncology therapy UCART123. Servier has already begun clinical testing with Cellectis' lead program, UCART19, in Europe. The product is licensed to Pfizer in the US.
You may also be interested in...
Major changes to Phase III Lung 100 study of PD-L1 inhibitor avelumab mean a big delay for development in first-line lung cancer, but, separately, Pfizer advances in allogeneic CAR-T therapy with partners Servier and Cellectis.
Novartis and Kite both are set to submit their CD19-targeting CAR-T therapies for US FDA approval in early 2017, while neurotoxic deaths for two of Juno’s product candidates cast doubts on its programs.
CRISPR techniques are just not accurate enough for the precision gene editing required for the scalable manufacture of CAR-T therapies, according to Cellectis CEO Andre Choulika. Cellectis has an 'off the shelf' CAR-T product for the treatment of leukemia which targets the CD19 antigen, the same target other companies in the CAR-T space such as Novartis, Kite Pharma and Juno Therapeutics are focused on.